Navigation Links
Pharma IQ's Solubility Report
Date:4/27/2012

LONDON, April 27, 2012 /PRNewswire/ --

Pharma IQ has just published the results of an industry-wide Solubility Report, conducted recently among 3,000 pharmaceutical solubility specialists.

The results showed that improving API solubility is the greatest challenge for nearly 60% of respondents, followed by exploring novel drug delivery routes (specified by 26% of respondents). The rest of the survey participants indicated improving API stability and formulation of biopharmaceuticals as the major issues.

In terms of improving compound solubility, the most popular compound modification strategies used by respondents were developing an amorphous form and adding an excipient. The least popular ones were changing the crystal structure and addition of a salt.

The report was created as a part of the pre-conference research for Improving Solubility Forum, taking place 26-28 June, 2012 in Munich.

The results helped to shape the agenda and final speaker line-up, which features David Elder, Externalisation Director from GlaxoSmithKline who will present his thoughts on model guided formulation development and Lennart Lindfords, Pharmaceutical and Analytical R&D from AstraZeneca, who will be leading a session on Computer Calculations of Poorly Soluble Drug Transport Across the Gastrointestinal Cell Wall.

Other important topics expressed by survey respondents and that will be discussed at the event include:

  • The Impact of Solubility During Pharmaceutical Research and Development (Christoph Saal, Senior Manager Molecule Characterisation, Merck)
  • The impact of surfactants on dissolution, in-vitro permeability and bioavailability of poorly soluble drugs (Menno Vliestra, Global Supply Chain, Finance and HR, Roche)
  • The use the knowledge and exp
    '/>"/>

SOURCE Pharma IQ
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 Advanced Wound ... Summary Advanced dressings have steadily replaced traditional ... a variety of wound indications, such as trauma ... infection control, and physical protection become increasingly critical ... role in standard therapy. This report focuses ...
(Date:9/2/2015)... , Sept. 2, 2015 About Duchenne ... X-linked disease, which generally affects the male population. ... weakness. The disease is caused due to mutations ... lack of production of dystrophin (a protein essential ... lack of dystrophin weakens muscle function, causes loss ...
(Date:9/2/2015)...   About ELISA test ELISA test ... is used for measuring the concentration of analytes such ... various types of enzymes such as carbonic anhydrase, glucose ... by photometry or fluorometry. ELISA is used as a ... such as HIV, pernicious anemia, rotavirus, Rocky Mountain spotted ...
Breaking Medicine Technology:Advanced Wound Dressings - SA Analysis and Market Forecasts 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3Global Enzyme-Linked Immunosorbent Assay (Elisa) Testing Market 2015-2019 2Global Enzyme-Linked Immunosorbent Assay (Elisa) Testing Market 2015-2019 3
... NATICK, Mass., June 20, 2011 Boston Scientific Corporation ... launch of its Mustang™ PTA Balloon Catheter, a highly ... for a wide range of peripheral angioplasty procedures.  The ... U.S., Europe and other international markets. ...
... International, Inc. (OTCQX: DATA), a technology and services ... clinical trials industry, today announced the expansion and ... ONE™.  The unified software suite consists of seven ... at the 2011 DIA National Meeting. ...
Cached Medicine Technology:Boston Scientific Announces Global Launch of Mustang™ PTA Balloon Catheter 2Boston Scientific Announces Global Launch of Mustang™ PTA Balloon Catheter 3DATATRAK Announces Expanded DATATRAK ONE™ Product Suite 2
(Date:9/2/2015)... Los Angeles, CA (PRWEB) , ... September 02, 2015 , ... ... entry featured by the Huffington Post on August 25th, writer Akela Stanfield detailed ... bariatric surgery. While the author acknowledged that she had always seen herself as someone ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... swamped with a large stream of mixed documents that include EOBs, payments, and ... documents, while extracting the data needed to reconcile their billing, with one efficient ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... Sciences clinical and academic partnership has earned international recognition as a premier center ... disorder that can cause sudden, catastrophic internal bleeding and stroke. , Cure ...
(Date:9/2/2015)... ... September 02, 2015 , ... Medical ... has completed a recapitalization with new investment partners Beecken Petty O’Keefe & ... each offer extensive expertise and connections within the healthcare industry, which makes ...
(Date:9/2/2015)... , ... September 02, 2015 , ... Amada Senior Care, ... office in Kansas – its Johnson County location. Amada franchise partners Mike ... has a registered nurse background and spent over 20 years in medical device sales ...
Breaking Medicine News(10 mins):Health News:Recent Editorial on Bariatric Surgery Acceptance Illuminates a Typical Journey Towards Weight Loss Surgery, Notes Dr. Michael Feiz 2Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 3Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 4Health News:Amada Senior Care Expands to Greater Kansas City 2
... Healthcare,Corporation (Nasdaq: UAHC ), which owns and ... organization in,Tennessee, today announced financial results for its ... increased 82 percent to $8.3 million for the ... revenues of $4.6 million for,the third quarter of ...
... MOUNTAIN VIEW, Calif., May 13 IRIDEX,Corporation (Nasdaq: IRIX ... ended March 29, 2008., Revenue for the first quarter ... million reported for the first quarter of 2007. The,Company,s net ... the,first quarter of 2008 compared with a net loss of ...
... for, Potential 2008 Launch of MOXATAG; Keflex Product Sales Total $2.4 ... ... GERMANTOWN, Md., May 13 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ... today,announced financial and operational results for the quarter ended March 31,2008., ...
... that treat the poor from improving, study finds , , TUESDAY, ... hospitals that treat poor and underserved patients, often called safety-net ... these patients, a new study finds. , These hospitals, which ... sources, do not have the money to improve the quality ...
... to treat a rare but well-known genetic disorder may hold ... potentially lethal enlarged hearts, due mainly to high blood pressure, ... common denominator in both phenylketonuria (PKU) and cardiac hypertrophy is ... helps break down the molecule phenylalanine whose buildup is toxic ...
... BLOOMFIELD HILLS, Mich., May 13 CJPS Enterprises, ... be holding a,half-day mini-seminar and interactive discussions about ... to increase their,competitiveness, and therefore their worth. This ... June 6th, 2008 and is applicable to both ...
Cached Medicine News:Health News:United American Healthcare Corporation Announces Fiscal 2008 Third Quarter Results 2Health News:United American Healthcare Corporation Announces Fiscal 2008 Third Quarter Results 3Health News:United American Healthcare Corporation Announces Fiscal 2008 Third Quarter Results 4Health News:United American Healthcare Corporation Announces Fiscal 2008 Third Quarter Results 5Health News:United American Healthcare Corporation Announces Fiscal 2008 Third Quarter Results 6Health News:United American Healthcare Corporation Announces Fiscal 2008 Third Quarter Results 7Health News:IRIDEX Reports First Quarter 2008 Financial Results 2Health News:IRIDEX Reports First Quarter 2008 Financial Results 3Health News:IRIDEX Reports First Quarter 2008 Financial Results 4Health News:IRIDEX Reports First Quarter 2008 Financial Results 5Health News:IRIDEX Reports First Quarter 2008 Financial Results 6Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 2Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 3Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 4Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 5Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 6Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 7Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 8Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 9Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 10Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 11Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 12Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 13Health News:Quality Lags at Safety-Net Hospitals 2Health News:Quality Lags at Safety-Net Hospitals 3Health News:Drug therapy for PKU reverses heart damage 2Health News:Drug therapy for PKU reverses heart damage 3Health News:Drug therapy for PKU reverses heart damage 4Health News:Intellectual Property Buildup Seminar to be Held in Detroit 2
... technology is here! LTF™ (Layered Thin Film) ... test platform that is easy to read, ... as a credit card. What is Infectious ... reason women visit their physician. Vaginal discharge ...
... test! QuickScreen multi-panel dip cards offer minimal ... choice of any conceivable combination of 9 ... for your drug testing program. Just dip ... built-in timer tells you when to read ...
... SureStep™ Drug Screen Tests are available in ... MDMA (Ecstasy). Designed using Microgenics Antibody Technology, ... only point of care immunoassay targeted to ... both MDA and MDEA but no cross-reactivity ...
Accu-Stat Home Drug Test for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (mAMP), Opiates (OPI), and Phencyclidine (PCP)....
Medicine Products: